Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
A study was carried out in six human volunteers, to assess the blood kinetics of isoniazid, rifampicin and pyrazinamide, administered in a fixed-triple combination intended for use in intermittent chemotherapy of tuberculosis. The formulation employed contained 125 mg of isoniazid (H), 100 mg of rifampicin (R) and 375 mg of pyrazinamide (Z) per tablet; six tablets were administered to every subject, giving a total dosage of 750 mg of isoniazid, 600 mg of rifampicin and 2,250 mg of pyrazinamide. In each subject, the same dose of each drug was administered individually in separate sessions and the results compared. The results indicated that, at the level of dose of the intermittent tablet, no negative interactions between the drugs were observed.
Acocella
G
G
Reference Center for Chemotherapy of Mycobacterial Diseases, IRCCS San Matteo Hospital, Pavia, Italy.
Luisetti
M
M
Grassi
G G
GG
Peona
V
V
Pozzi
E
E
Grassi
C
C
D000328:Adult; D001682:Biological Availability; D002214:Capsules; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006207:Half-Life; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008297:Male; D011718:Pyrazinamide / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D012293:Rifampin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D013607:Tablets; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D002214:Capsules; D004338:Drug Combinations; D013607:Tablets; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin